altRX vs Nalena
altRX and Nalena both sell semaglutide and tirzepatide; this is how their prices, coverage and records differ.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Nalena
Best for: coverage in all 50 states, which most sellers will not confirm
Visit Nalena →If you are choosing between altRX and Nalena, price alone will not settle it. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. altRX leads our six-part score, 7.6 to 7.3. One of the two has an FDA warning letter on record, covered below.
altRX vs Nalena price
altRX and Nalena start at the same figure, $149 a month, so the entry price does not separate them. Look at what each price covers and at the per-drug prices below.
Drug by drug: Semaglutide costs the same at both, $149 a month; tirzepatide is cheaper at Nalena ($149 a month vs $249 a month).
Medications and formats
Both sell semaglutide and tirzepatide.
On format, altRX prices compounded injections and brand-name pens, while Nalena prices compounded injections.
If you want the FDA-approved brand rather than a compounded version, altRX is the only one of the two with a brand-name price.
Where each one treats patients
altRX lists 50 states, and Nalena lists 50 states.
They overlap in 50 states.
Pricing
altRX
Nalena
What each price covers
Both prices cover the clinician visit, the medication itself and shipping.
altRX is silent on lab work and coaching.
Nalena is silent on lab work and coaching.
altRX
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Nalena
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Where each one scores higher
Overall, altRX scores 7.6 and Nalena 7.3 out of 10.
altRX is stronger on value (5.0 vs 3.0).
Nalena is stronger on trust & safety (7.5 vs 6.0).
Effectiveness, user experience, accessibility and support are within half a point.
altRX
7.6/10
Nalena
7.3/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent altRX a warning letter dated June 8, 2026 (letter 728236), and it is still open.
Nalena has no FDA warning letter on record with us.
Features & Coverage
| Feature | altRX | Nalena |
|---|---|---|
| Starting Price | $149/mo | $149/mo |
| Features | 8 features | 8 features |
| States Available | 50 | 50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | 1 letter | ✓None |
About altRX
Compounded plans open at $149 for semaglutide and $249 for tirzepatide. Branded medication runs $1,149-$1,579, a figure that already contains the consult and the shipping. Every one of the four FDA-approved brands is stocked, Mounjaro, Ozempic, Wegovy and Zepbound, which no other entry in our directory matches. altRX works in both modalities, holds LegitScript certification, and prints the FDA compounded-medication disclaimer.
Read our full altRX review →About Nalena
Nalena starts at $149/month with medication included and no separate membership or visit fees. The women-focused platform sells only compounded semaglutide and tirzepatide, and leans on transparency in its positioning: no hidden fees, cancel anytime, and a money-back guarantee uncommon among compounded sellers. No insurance is required and 2-day shipping is free. Clinical care is delivered by Beluga Health, P.A.
Read our full Nalena review →Pros & Cons
altRX
What we like
- Tirzepatide costs $1249 a month, close to the $1249 median for brand-name tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication, clinician visits and shipping
- Serves all 50 states
- Names 4 pharmacies that fill its prescriptions, which most sellers do not
Watch-outs
- Semaglutide costs $1149 a month, 15% above the $997 median for brand-name semaglutide across the sellers we compare
- The FDA has issued altRX a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Nalena
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication, clinician visits and shipping
- Serves all 50 states
- We found no FDA warning letters issued to Nalena
Watch-outs
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
altRX wins this one, 7.6 to 7.3, above all for semaglutide from $1149/month. Nalena fits better if coverage in all 50 states, which most sellers will not confirm is your priority.
Choose altRX if…
You want semaglutide from $1149/month and an opening price near $149 a month.
Choose Nalena if…
You want coverage in all 50 states, which most sellers will not confirm and an opening price near $149 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Trimi Health
Knowing which pharmacy fills the vial: it names VialsRx
From $99/mo
Get started →ShedRx
Oral orforglipron alongside the injectables
From $149/mo
Get started →bmiMD
Starting below a standard dose, with microdose tiers
From $99/mo
Get started →altRX vs Nalena: FAQ
Close alternatives to altRX and Nalena
- altRX vs Gala
- altRX vs Sprout Health
- altRX vs Aquivia Health
- altRX vs Vytora Health
- Nalena vs Trinity Meds
- Nalena vs PlushCare
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.